Pillar 1 - FTO (new thread), page-36

There are some big caveats on obesity though, IMO:

- To state the obvious, Race would have to prove it could work as an anti-obesity agent through clinical research.
- Then, it's a different game to get it approved. FDA may eagerly approve salvage drugs for patients in advanced cancer stage, given it is a life-or-death situation which outweights any potential risks for patients. In comparison, obesity is not life-threatening and would be scrutinised for side effects. Back in 2006, Sanofi got burnt with Acomplia.

Case: Accomplia/Rimonabant is a a cannabinoid receptor antagonist that blocks the signals of hunger. The drug worked very well and was was approved, expected to be a blockbuster, but some patients anecdotically reported an increase in depression/suicidal thoughts. which pushed FDA and other regulators to withdraw approval. Acomplia when from blockbuster to bust.

https://www.fiercepharma.com/special-report/acomplia-pharma-s-biggest-flops

Bisantrene has a totally different acting mechanism compared to Acomplia. Instead of interfering with brain signals it actually meddles with cell/DNA reproduction, which from my unqualified opinion would place it much higher on the scale of risks.

IMHO and would be great to have an expert opinion on this. Dr T perhaps?